About Protein unc-93 homolog A
Protein unc-93 homolog A (UNC93A) is a protein
from Homo sapiens identified by UniProt accession
Q86WB7, 457 residues long.
MolForge cross-references it against 0 known binders and
21 disease associations.
Target properties
| Protein name | Protein unc-93 homolog A |
| UniProt accession | Q86WB7 |
| Gene | UNC93A |
| Organism | Homo sapiens |
| Length | 457 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (21)
Diseases linked to this target (Open Targets).
- serum metabolite measurement · score 0.44
- urinary metabolite measurement · score 0.40
- self reported educational attainment · score 0.05
- Crohn's disease · score 0.04
- non-small cell lung carcinoma · score 0.03
- ovarian cancer · score 0.03
- neoplasm · score 0.02
- colorectal adenocarcinoma · score 0.02
- psoriasis · score 0.02
- colorectal cancer · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86WB7-F1 | alphafold | PREDICTED | 85.14 | — |
Amino-acid sequence (457 residues)
MDRSLRNVLV VSFGFLLLFT AYGGLQSLQS SLYSEEGLGV TALSTLYGGM LLSSMFLPPL LIERLGCKGT IILSMCGYVA FSVGNFFASW YTLIPTSILL GLGAAPLWSA QCTYLTITGN THAEKAGKRG KDMVNQYFGI FFLIFQSSGV WGNLISSLVF GQTPSQETLP EEQLTSCGAS DCLMATTTTN STQRPSQQLV YTLLGIYTGS GVLAVLMIAA FLQPIRDVQR ESEGEKKSVP FWSTLLSTFK LYRDKRLCLL ILLPLYSGLQ QGFLSSEYTR SYVTCTLGIQ FVGYVMICFS ATDALCSVLY GKVSQYTGRA VLYVLGAVTH VSCMIALLLW RPRADHLAVF FVFSGLWGVA DAVWQTQNNA LYGVLFEKSK EAAFANYRLW EALGFVIAFG YSMFLCVHVK LYILLGVLSL TMVAYGLVEC VESKNPIRPH APGQVNQAED EEIQTKM
Explore Protein unc-93 homolog A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets